MCP & Models

Give your AI
the full picture.

Keep Claude, ChatGPT or your own agent. Add Gosset’s connected pharma data and predictive models.

Connect your assistant

Claude
ChatGPT
Your agents

Gosset

Data

Drugs
Trials
Results
Targets
Companies
Deals

Predictive models

Probability of trial success
Trial timelines
Asset valuation

The difference in practice

Same question.
More to work with.

A broader evidence base gives your assistant more of the landscape to reason about.

Example query results from Claude alone and Claude with Gosset.
Question	Claude	Claude + Gosset
Which China-origin ADCs now in Phase 2 or 3 have licensing agreements with US partners since 2023? Data pulled · 8 Sept 2026	2licensing programs	4licensing programsAcross 4 distinct ADC assets
What’s the competitive landscape of TL1A? Data pulled · 1 Sept 2026	9assets	52assetsPipeline, trials & ownership

Broader coverage

Find the connections across assets, trials, companies and deals.

Faster answers

Pull relevant records directly, with less searching and extraction.

Less token overhead

Spend fewer tokens gathering evidence and more on the analysis.

Go beyond retrieval

State-of-the-art predictive models

Leverage accurate, calibrated forecasts trusted by top-30 pharma.

Probability of success: How likely is this trial to succeed?
Trial timelines: When could the next milestone arrive?
Asset valuation: What does the evidence imply for value?

Forecasts evaluated against observed outcomes, using point-in-time data.

How we measure accuracy

Models are evaluated out of sample against known outcomes. In our trial completion-date evaluation, predictions landed a median of 47 days closer to the actual date than sponsor estimates. Probability-of-success estimates are assessed with calibration curves.

Works where you work